Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 208

1.

The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli.

Park SH, Choi SM, Chang YK, Lee DG, Cho SY, Lee HJ, Choi JH, Yoo JH.

J Antimicrob Chemother. 2014 Oct;69(10):2848-56. doi: 10.1093/jac/dku215. Epub 2014 Jun 13.

2.

Impact of extended-spectrum β-lactamase production on treatment outcomes of acute pyelonephritis caused by escherichia coli in patients without health care-associated risk factors.

Park SH, Choi SM, Lee DG, Cho SY, Lee HJ, Choi JK, Choi JH, Yoo JH.

Antimicrob Agents Chemother. 2015 Apr;59(4):1962-8. doi: 10.1128/AAC.04821-14. Epub 2015 Jan 12.

3.

Impact of extended-spectrum beta-lactamase on acute pyelonephritis treated with empirical ceftriaxone.

Lee S, Song do Y, Cho SH, Kwon KT.

Microb Drug Resist. 2014 Feb;20(1):39-44. doi: 10.1089/mdr.2013.0075. Epub 2013 Aug 13.

PMID:
23941639
4.

Aminoglycoside therapy for childhood urinary tract infection due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.

Han SB, Lee SC, Lee SY, Jeong DC, Kang JH.

BMC Infect Dis. 2015 Oct 13;15:414. doi: 10.1186/s12879-015-1153-z.

6.

High rate of per oral mecillinam treatment failure in community-acquired urinary tract infections caused by ESBL-producing Escherichia coli.

Søraas A, Sundsfjord A, Jørgensen SB, Liestøl K, Jenum PA.

PLoS One. 2014 Jan 15;9(1):e85889. doi: 10.1371/journal.pone.0085889. eCollection 2014.

7.

Outcomes and risk factors for mortality in community-onset bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli, with a special emphasis on antimicrobial therapy.

Kang CI, Wi YM, Ko KS, Chung DR, Peck KR, Lee NY, Song JH.

Scand J Infect Dis. 2013 Jul;45(7):519-25. doi: 10.3109/00365548.2013.775479. Epub 2013 Mar 19.

PMID:
23509913
9.

Extended-spectrum β-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy.

Meier S, Weber R, Zbinden R, Ruef C, Hasse B.

Infection. 2011 Aug;39(4):333-40. doi: 10.1007/s15010-011-0132-6. Epub 2011 Jun 25.

PMID:
21706226
10.

β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts.

Rodríguez-Baño J, Navarro MD, Retamar P, Picón E, Pascual Á; Extended-Spectrum Beta-Lactamases–Red Española de Investigación en Patología Infecciosa/Grupo de Estudio de Infección Hospitalaria Group.

Clin Infect Dis. 2012 Jan 15;54(2):167-74. doi: 10.1093/cid/cir790. Epub 2011 Nov 4.

11.

Clinical and molecular epidemiology of community-onset, extended-spectrum beta-lactamase-producing Escherichia coli infections in Thailand: a case-case-control study.

Apisarnthanarak A, Kiratisin P, Saifon P, Kitphati R, Dejsirilert S, Mundy LM.

Am J Infect Control. 2007 Nov;35(9):606-12.

PMID:
17980240
12.

Emergence of extended-spectrum β-lactamase-producing escherichia coli as a cause of community-onset bacteremia in South Korea: risk factors and clinical outcomes.

Park SH, Choi SM, Lee DG, Kim J, Choi JH, Kim SH, Kwon JC, Yoo JH.

Microb Drug Resist. 2011 Dec;17(4):537-44. doi: 10.1089/mdr.2011.0072. Epub 2011 Aug 29.

PMID:
21875342
13.

Rise of community-onset urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli in children.

Fan NC, Chen HH, Chen CL, Ou LS, Lin TY, Tsai MH, Chiu CH.

J Microbiol Immunol Infect. 2014 Oct;47(5):399-405. doi: 10.1016/j.jmii.2013.05.006. Epub 2013 Jul 6.

14.

Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases.

Calbo E, Romaní V, Xercavins M, Gómez L, Vidal CG, Quintana S, Vila J, Garau J.

J Antimicrob Chemother. 2006 Apr;57(4):780-3. Epub 2006 Feb 21.

15.

Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.

Tamma PD, Han JH, Rock C, Harris AD, Lautenbach E, Hsu AJ, Avdic E, Cosgrove SE; Antibacterial Resistance Leadership Group.

Clin Infect Dis. 2015 May 1;60(9):1319-25. doi: 10.1093/cid/civ003. Epub 2015 Jan 13. Erratum in: Clin Infect Dis. 2015 Jul 1;61(1):143.

16.

Antibiotic resistance in adult female patients hospitalized for acute pyelonephritis: rates and predicting factors.

Etienne M, Van Elslande H, Choplin-Renard J, Pestel-Caron M, Caron F.

Med Mal Infect. 2014 May;44(5):217-22. doi: 10.1016/j.medmal.2014.03.003. Epub 2014 Apr 28.

PMID:
24787633
17.

Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge.

Rodríguez-Baño J, Navarro MD, Romero L, Muniain MA, de Cueto M, Ríos MJ, Hernández JR, Pascual A.

Clin Infect Dis. 2006 Dec 1;43(11):1407-14. Epub 2006 Oct 25.

18.

Clinical and bacteriological efficacy of amikacin in the treatment of lower urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae.

Ipekci T, Seyman D, Berk H, Celik O.

J Infect Chemother. 2014 Dec;20(12):762-7. doi: 10.1016/j.jiac.2014.08.007. Epub 2014 Aug 30.

PMID:
25179392
19.

Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection.

Senol S, Tasbakan M, Pullukcu H, Sipahi OR, Sipahi H, Yamazhan T, Arda B, Ulusoy S.

J Chemother. 2010 Oct;22(5):355-7.

PMID:
21123160
20.

Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis.

Rodríguez-Baño J, Picón E, Gijón P, Hernández JR, Ruíz M, Peña C, Almela M, Almirante B, Grill F, Colomina J, Giménez M, Oliver A, Horcajada JP, Navarro G, Coloma A, Pascual A; Spanish Network for Research in Infectious Diseases (REIPI).

Clin Infect Dis. 2010 Jan 1;50(1):40-8. doi: 10.1086/649537.

Items per page

Supplemental Content

Write to the Help Desk